NCT00193258View on ClinicalTrials.gov

Bevacizumab, Erlotinib, and Imatinib in the Treatment of Advanced Renal Cell Carcinoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

94

Participants

Timeline

Start Date

June 30, 2004

Primary Completion Date

January 31, 2011

Study Completion Date

August 31, 2011

Conditions
Clear Cell Renal Cell Carcinoma
Interventions
DRUG

Bevacizumab

10mg/kg IV infusion every 2 weeks

DRUG

Erlotinib

150 mg po daily

DRUG

Imatinib

400-600mg daily

Sponsors

Collaborators (2)

Genentech, Inc.
Novartis
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

collaborator

Novartis

INDUSTRY

lead

SCRI Development Innovations, LLC

OTHER